Home / Learn / Resource Detail

Clarifying the Role of Maintenance Therapy - [Video Podcast] Ep 40

March 14, 2024

Maintenance therapy for patients with acute myeloid leukemia, particularly those who are ineligible for transplant, can be critical to treatment outcomes and quality of life for patients. In this episode, CANCER BUZZ speaks with Thomas LeBlanc, MD, hematologic oncologist, associate professor of Medicine, and associate professor in Population Health Sciences at Duke Cancer Institute, about the importance of keeping patients with acute myeloid leukemia in first remission as long as possible through maintenance therapy. 

 
“You have to be aware of the benefits of maintenance therapy…and for patients who are being considered for transplant but who do not end up getting a transplant, it should really be the default option that those patients receive a maintenance therapy.” –Thomas W. LeBlanc, MD

 

Guests

Thomas W. LeBlanc, MD

Hematologic Oncologist,

Associate Professor of Medicine,

Associate Professor in Population Health Sciences

Duke Cancer Network, Duke Cancer Institute

Durham, North Carolina
 

 

This is the fourth and final episode of a four-part series developed in connection with the ACCC education program Achieving and Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia. This episode was made possible with support by Bristol Myers-Squibb.

Resources:  


    The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.